VANDETANIB, DESIGNED TO INHBIT VEGFR2 AND EGFR SIGNALLING, HAD NO CLINICAL ACTIVITY AS MONOTHERAPY FOR RECURRENT OVARIAN CANCER AND NO DETECTABLE MODULATION OF VEGFR2
C. Annunziata, A. Walker, L. Minasian, Minshu Yu +7 more
2010Clinical Cancer Research79 citations Open access
Semantic Scholar

